Merck Boosts Lobbying Expenses by 38 pct
Merck Boosts Lobbying Expenses by 38 pct
March 16, 2010 /EIN PRESSWIRE/ To have its voice heard in the healthcare debate, Merck & Co. boosted its lobbying efforts by 38% to $1.8 million in Q4 2009, the Associated Press reports.
Merck lobbied against allowing government price controls on drugs purchased by the Medicare program and against increasing rebates that drug makers pay to the government under the Medicaid program, the AP writes. The company lobbied for access through Medicare to vaccines for the elderly as well as increasing funding for the National Immunization Program. Merck is the top manufacturer of children's vaccines.
Read more about Merck's lobbying efforts at Merck Daily Report:
Merck Vaccines news - http://merck.einnews.com/news/merck-vaccines
United States Merck news - http://merck.einnews.com/unitedstates/
Located at http://merck.einnews.com, Merck Daily Report is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest Merck news from around the world, saving them valuable time they'd spend searching for information. New users to Merck Daily Report can enjoy a no-obligation, one-week free trial.
About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.
March 16, 2010 /EIN PRESSWIRE/ To have its voice heard in the healthcare debate, Merck & Co. boosted its lobbying efforts by 38% to $1.8 million in Q4 2009, the Associated Press reports.
Merck lobbied against allowing government price controls on drugs purchased by the Medicare program and against increasing rebates that drug makers pay to the government under the Medicaid program, the AP writes. The company lobbied for access through Medicare to vaccines for the elderly as well as increasing funding for the National Immunization Program. Merck is the top manufacturer of children's vaccines.
Read more about Merck's lobbying efforts at Merck Daily Report:
Merck Vaccines news - http://merck.einnews.com/news/merck-vaccines
United States Merck news - http://merck.einnews.com/unitedstates/
Located at http://merck.einnews.com, Merck Daily Report is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest Merck news from around the world, saving them valuable time they'd spend searching for information. New users to Merck Daily Report can enjoy a no-obligation, one-week free trial.
About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.